BioPharm Insight recently ranked Goodwin among the most active legal advisers for global, North American and European biotech and pharma licensing agreements for the 12 months ending June 30, 2014. In the trailing twelve months, Goodwin advised on 27 licensing agreements collectively valued at more than USD$3.5 billion, resulting in the following rankings:
- #1 in global volume (27 deals, USD$3.551 billion)
- #1 in North American volume (27 deals, USD$3.551 billion)
- #1 in European volume (15 deals, USD$2.311 billion)
Goodwin also ranked in the top three for deal value in each of the global, North American and European value tables.
“We are delighted to be recognized as the leading global law firm for licensing transactions. This accolade is a testament to the depth, sophistication and geographic breadth of our transaction teams, who take pride in advising many of the industry’s most promising companies in their transformational business agreements,” said Goodwin partner Kingsley Taft.
Goodwin’s Life Sciences Practice is regularly recognized for its excellence and has twice been named the Law Firm of the Year in Biotechnology Law by U.S. News-Best Lawyers (2014, 2013). The practice represents more than 400 private and public life sciences companies, from start-ups to Fortune 100 corporations, as well as 200 private equity, venture capital and investment banking companies. The practice includes more than 100 attorneys and is co-chaired by partners Mitchell Bloom and Kingsley Taft.